Trade

with

Vical Inc
(NASDAQ: VICL)
AdChoices
1.20
+0.01
+0.84%
After Hours :
1.21
+0.01
+0.83%

Open

1.18

Previous Close

1.19

Volume (Avg)

289.92k (622.39k)

Day's Range

1.16-1.21

52Wk Range

1.01-1.79

Market Cap.

106.33M

Dividend Rate ( Yield )

-

Beta

1.55

Shares Outstanding

88.60M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 7.72M

    • Net Income

    • -31.24M

    • Market Cap.

    • 106.33M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -168.13

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.55

    • Forward P/E

    • -6.49

    • Price/Sales

    • 8.98

    • Price/Book Value

    • 1.87

    • Price/Cash flow

    • -5.78

      • EBITDA

      • -29.14M

      • Return on Capital %

      • -27.78

      • Return on Equity %

      • -30.47

      • Return on Assets %

      • -27.78

      • Book Value/Share

      • 0.64

      • Shares Outstanding

      • 88.60M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 1.40

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • 0.47

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 209.40

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -0.61

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -9.09

            • 82.75

            • Pre-Tax Margin

            • -168.13

            • 39.38

            • Net Profit Margin

            • -168.13

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 19.10

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -226.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 14.26

              • 2.92

              • Quick Ratio

              • 13.44

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.09

              • 2.21

              • Book Value/Share

              • 0.64

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.56

                • 196.08

                • P/E Ratio 5-Year High

                • -23.60

                • 634.30

                • P/E Ratio 5-Year Low

                • -4.50

                • 124.82

                • Price/Sales Ratio

                • 9.35

                • 9.12

                • Price/Book Value

                • 1.95

                • 8.26

                • Price/Cash Flow Ratio

                • -5.78

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -30.47

                    (-38.00)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -27.78

                    (-33.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -30.47

                    (-38.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.17

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -31.35M
                  Operating Margin
                  -406.22
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -5.78
                  Ownership

                  Institutional Ownership

                  42.43%

                  Top 10 Institutions

                  35.83%

                  Mutual Fund Ownership

                  13.43%

                  Float

                  89.32%

                  5% / Insider Ownership

                  2.23%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    5,921,845

                  • 0.00

                  • 6.68

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,293,153

                  • 0.00

                  • 1.46

                  • Fidelity® Small Cap Stock Fund

                  •  

                    1,200,000

                  • -10.19

                  • 1.35

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    659,862

                  • 0.00

                  • 0.74

                  • Vanguard Extended Market Index Fund

                  •  

                    579,209

                  • 6.00

                  • 0.65

                  • Ariel Discovery Fund

                  •  

                    437,800

                  • 0.00

                  • 0.49

                  • TFS Market Neutral Fund

                  •  

                    424,212

                  • -56.08

                  • 0.48

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    229,477

                  • 0.00

                  • 0.26

                  • iShares Micro-Cap

                  •  

                    224,011

                  • 1.28

                  • 0.27

                  • Bridgeway Ultra Small Company Market

                  •  

                    100,000

                  • 17.68

                  • 0.11

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    7,635,865

                  • -6.72%

                  • 8.69

                  • Ariel Investments, LLC

                  •  

                    5,795,210

                  • 0.00%

                  • 6.60

                  • Federated Investment Management Company

                  •  

                    2,887,672

                  • -58.01%

                  • 3.33

                  • BlackRock Fund Advisors

                  •  

                    2,742,706

                  • -16.23%

                  • 3.12

                  • Vanguard Group, Inc.

                  •  

                    1,915,091

                  • -4.93%

                  • 2.18

                  • Technical Financial Services LLC

                  •  

                    1,174,864

                  • -41.99%

                  • 1.34

                  • D. E. Shaw & Co LP

                  •  

                    1,015,746

                  • -2.79%

                  • 1.16

                  • Northern Trust Investments, N.A.

                  •  

                    744,500

                  • -19.86%

                  • 0.85

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Value

                  Vical Inc a Delaware corporation, was incorporated in April 1987. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-thre...moreatening diseases. It has three active or partnered development programs in the area of infectious disease comprising of an ongoing Phase 3 clinical trial of ASP0113 for prevention of cytomegalovirus, or CMV, reactivation in stem cell transplant recipients and an ongoing Phase 2 clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients, both in collaboration with Astellas Pharma Inc., or Astellas; An ongoing Phase 1/2 clinical trial using our Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2, or HSV-2, a cause of recu...morerrent genital herpes; and a completed preclinical program, with an allowed investigational new drug application, or IND, using our CyMVectin prophylactic vaccine formulated with our proprietary Vaxfectin adjuvant to prevent CMV infection before and during pregnancy. The Company has leveraged its patented technologies through licensing and collaboration arrangements, such as its licensing arrangements with Astellas, AnGes MG, Inc., or AnGes, Aqua Health Ltd. of Canada, or Aqua Health, an affiliate of Novartis Animal Health, and Merial Limited, or Merial, a subsidiary of Sanofi, among other biopharmaceutical companies. In addition, it has licensed complementary technologies from research institutions and biopharmaceutical companies. The Company has also granted non-exclusive, academic licenses to its DNA delivery technology patent estate to 11 research institutions including Stanford, Harvard, Yale and the Massachusetts Institute of Technology, or MIT. The Company’s key discovery to its patented core DNA delivery technology was that muscle tissues can take up polynucleotide genetic material, such as DNA or RNA, directly, without the use of viral components or other delivery vehicles or technologies, and subsequently express the proteins encoded by the genetic material for periods ranging from weeks to more than a year. Its DNA delivery technology is being developed by the company and its partners in two areas of application, such as Infectious Diseases and Veterinary. The Company is aware of several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are engaged in infectious disease vaccine research and development. These include Sanofi, Novartis, GlaxoSmithKline PLC, MedImmune, Inc., a wholly owned subsidiary of AstraZeneca, Merck and Pfizer Inc., among others. Roche, Sanofi, AiCuris GmbH & Co. KG in conjunction with Merck, Chimerix, Inc., and others have products or development programs for CMV treatment and prevention. GlaxoSmithKline plc., Genocea Biosciences, Inc., Agenus, Inc. and others have products or development programs for HSV-2 treatment. New gene-based products for vaccine or therapeutic applications are subject to extensive regulation by the FDA and comparable agencies in other countries. The potential products will be regulated either as biological products or as drugs. In the United States, drugs are subject to regulation under the Federal Food, Drug and Cosmetic Act, or the FDC Act. Biological products, in addition to being subject to provisions of the FDC Act, are regulated in the United States under the Public Health Service Act. Both statutes and related regulations govern, among other things, testing, manufacturing, safety, efficacy, labeling, storage, record keeping, advertising, and other promotional practices.lessless

                  Key People

                  Mr. Vijay B. Samant

                  CEO/Director/President

                  Dr. R. Gordon Douglas,M.D.

                  Chairman of the Board/Director

                  Dr. Larry R. Smith,PhD

                  Vice President, Divisional

                  Mr. Anthony A. Ramos

                  Chief Accounting Officer/Vice President, Divisional

                  Dr. Robert C. Merton,PhD

                  Director

                  • Vical Inc

                  • 10390 Pacific Center Court

                  • San Diego, CA 92121-4340

                  • USA.Map

                  • Phone: +1 858 646-1100

                  • Fax: +1 858 646-1150

                  • vical.com

                  Incorporated

                  1987

                  Employees

                  67

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: